PeerView Internal Medicine CME/CNE/CPE Video Podcast
772 episodes - English - Latest episode: 9 days ago - ★★★★★ - 2 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Julie V. Philley, MD; Kevin Winthrop, MD, MPH - Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment
August 29, 2022 23:00 - 34 minutes VideoGo online to PeerView.com/MNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live webcast, two experts in NTM-LD who represent pulmonology and infectious disease will offer their perspectives to help you achieve greater insight into the recognition and diagnosis of NTM-LD. You will hear the most up-to-date evidence on the management of NTM-LD, including both pharmacologic and nonpharmacologic approach...
Aditya Bardia, MD, MPH - Candid Conversations and Clinical Consults in Community Context: Practical Guidance for Integrating TROP2-Targeting ADCs Into Patient-Centric Breast Cancer Clinical Care
August 29, 2022 23:00 - 50 minutes VideoGo online to PeerView.com/JWM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in the management of patients with hormone receptor–positive breast cancer discuss the latest advances with TROP2-targeting antibody–drug conjugates (ADCs). Produced in collaboration with Living Beyond Breast Cancer and METAvivor, this program features a patient explaining her journey from diagnosis to participation in an important cli...
Rupa R. Patel, MD, MPH, DTM&H - A Closer Look at Telehealth for PrEP: Best Practices for PrEP Delivery in a Unique Era of Care
August 29, 2022 23:00 - 37 minutes VideoGo online to PeerView.com/AHC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in HIV prevention discuss how telehealth has transformed access to quality PrEP services in the era of COVID-19 and resources available to help clients in maximizing the full benefits of innovative HIV prevention measures. Upon completion of this activity, participants should be better able to: Discuss how telehealth has transformed ac...
Beth Faiman, PhD, RN, MSN, ANP-BC, AOCN, FAAN - Reaching the Next Level of Myeloma Patient Care: Oncology Nurse Guidance on Antibody Therapy and Novel Mechanisms of Action
August 25, 2022 23:00 - 35 minutes VideoGo online to PeerView.com/BRG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This activity provides a model for “next-level” nursing practice in multiple myeloma (MM) by linking current evidence supporting the use of innovative antibody, CAR-T, and targeted treatment platforms with case-based teaching examples designed to cover the spectrum of myeloma care. Furthermore, experts give guidance on nursing principles, including educational ...
Alexander Drilon, MD - Uncovering Gene Fusions and Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment
August 25, 2022 23:00 - 1 hour VideoGo online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat su...
Professor Perry Elliott, MBBS, MD, FRCP, FESC, FACC - New Therapies, New Hope: Evolving Strategies for Improving Outcomes and Quality of Life in Patients With Hypertrophic Cardiomyopathy
August 25, 2022 23:00 - 49 minutes VideoGo online to PeerView.com/WKU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Hypertrophic cardiomyopathy (HCM) is estimated to affect as many as 15 to 20 million people worldwide. However, it remains frequently undetected, because its symptoms are often nonspecific or mistaken for more common conditions. In this discussion-based activity, leading experts on HCM get to the heart of the matter, diagnosis and treatment, as they review guid...
Robert Z. Orlowski, MD, PhD - Building Real-World Bridges Between Clinicians and Patients With Myeloma: Guidance on Innovative Antibody Options
August 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/JPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further integration of different antibody-based approaches into patient management. How can professionals exploit these advances while using the principles of shared decision-making when caring for patients? In this activity, two hematologist-oncologists and a patien...
Elena Elez, MD, PhD - Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
August 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/NEB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. How can recent advances in managing HER2-positive GI cancers be used to further improve outcomes for patients? With the validation of novel HER2-targeted agents in gastric, colorectal, and other GI malignancies, this has become the central therapeutic question—one that can be answered by a combination of evidence-based HER2 testing and the integration of modern...
Domenica M. Rubino, MD - Getting Ahead of the Curve: Identifying and Managing Obesity in Primary Care
August 11, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DBP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on obesity management discusses current evidence for anti-obesity medications and shares evidence-based strategies to individualize weight-loss regimens and improve health outcomes. Upon completion of this activity, participants should be better able to: Recognize the role of weight-loss pharmacotherapy for reducing risks and address...
Richard Beaser, MD - A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes
August 10, 2022 23:00 - 1 hour VideoGo online to PeerView.com/TFR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Who holds the key that can unlock the door to vision-saving treatments for patients with diabetic retinopathy (DR) and diabetic macular edema (DME)? The answer is primary diabetes care professionals: Timely screening and referral to eye care professionals can make a real difference between good vision and blindness for patients with DR/DME. The diagnosis and tr...
David Cornblath, MD - Optimizing Outcomes in Chronic Inflammatory Demyelinating Polyneuropathy: Honing Diagnostic Accuracy, Personalizing Treatment Plans
August 10, 2022 23:00 - 26 minutes VideoGo online to PeerView.com/FJH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated educational activity, an expert in chronic inflammatory demyelinating polyneuropathy (CIDP) discusses the diagnosis, assessment, treatment, and monitoring of the disease. A patient also shares her experiences living with and treating her CIDP. Upon completion of this activity, participants should be better able to: Apply guideline-directed crit...
Prof. Carmelo Rizzari - The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients
August 10, 2022 23:00 - 1 hour VideoGo online to PeerView.com/JFN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Optimized use of asparaginase is a cornerstone of successful administration of multiagent chemotherapy in acute lymphoblastic leukemia (ALL) and has implications for patient outcomes across populations—are you prepared for the emergence of novel asparaginase formulations and the use of strategies that can help avoid treatment discontinuation? This MasterClass &...
Sagar Lonial, MD, FACP - Navigating From A to B and C in Multiple Myeloma: Delivering High-Quality Care With mAbs, BCMA ADCs, and Cellular Therapy
August 09, 2022 23:00 - 1 hour VideoGo online to PeerView.com/VDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The modern management of multiple myeloma (MM) continues to be transformed by the emergence and further development of immunotherapeutics, including antibody-based agents directed against targets such as CD38 and BCMA, as well as emerging BCMA CAR-T cell therapy options. These new “ABCs” of myeloma management now represent the cornerstone of high-quality, colla...
Yelena Y. Janjigian, MD - Moving the Treatment of Advanced Gastroesophageal Cancers Forward: How Can We Maximize the Benefits of Novel Immunotherapy Approaches?
August 09, 2022 23:00 - 47 minutes VideoGo online to PeerView.com/NTS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recently approved immunotherapy options have revolutionized the treatment of patients with advanced gastroesophageal cancers (eg, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, esophageal squamous cell carcinoma [ESCC]), which have traditionally been associated with poor outcomes due to late detection, high heteroge...
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD / Anthony R. Mato, MD, MSCE - Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL
August 09, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DQM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to the challenge of selecting and sequencing BTK inhibitor options in difficult B-cell cancer settings? This PeerView MasterClass and Case Forum activity recorded at the European hematology annual meeting explores BTK inhibitors as highly effective therapeutic tools for treating R/R CLL/SLL and MCL; join the experts and learn about important evidence...
Jacob Sands, MD - Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes
August 05, 2022 23:00 - 1 hour VideoGo online to PeerView.com/VDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting...
Hussein A. Tawbi, MD, PhD - New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
August 05, 2022 23:00 - 1 hour VideoGo online to PeerView.com/ZBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Treatment advances in metastatic melanoma have been characterized by the use of immunotherapy, including PD-1 and CTLA-4 checkpoint inhibitors, as well as targeted agents in BRAF-mutated disease—and collectively these modalities represent the driving forces leading to improved clinical outcomes across disease settings. How will new evidence change this current ...
Michael B. Atkins, MD - Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease
August 05, 2022 23:00 - 1 hour VideoGo online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundation...
Bruce Cree, MD, PhD, MAS - Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
August 05, 2022 23:00 - 1 hour VideoGo online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of ...
Leonard H. Calabrese, DO - Recognition and Management of Axial Spondyloarthritis: Best Practices for Family Medicine Physicians
August 05, 2022 23:00 - 43 minutes VideoGo online to PeerView.com/RBU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the recognition of axial spondyloarthritis (axSpA) and integrating the latest evidence into the management of patients with axSpA. Upon completion of this activity, participants should be better able to: Identify the specific domains of axial spondyloarthritis (axSpA) and their relationship to quality of life; Apply classif...
Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP - The Power of Team-Based Care and Novel Therapies in Alopecia Areata and Atopic Dermatitis: What Advanced Care Providers Need to Know
August 02, 2022 23:00 - 1 hour VideoGo online to PeerView.com/REA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Listen to our expert faculty as they discuss new and emerging therapies for AA and AD, with a focus on mechanisms of action, efficacy and safety profiles, nuances of administration and use, and risk:benefit profile. You will also hear about novel therapies in late-stage development for the treatment of moderate to severe AD and AA. The Late Night inExchange for...
Anthony R. Mato, MD, MSCE - Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care
August 02, 2022 23:00 - 1 hour VideoGo online to PeerView.com/JJJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you ready to make personalized treatment choices with the potent suite of targeted agents, including BTK and BCL-2 inhibitors, that have become standards of care in chronic lymphocytic leukemia (CLL)? In collaboration with the CLL Society, this PeerView MasterClass & Case Forum, based on a live event at the ASCO Annual Meeting, will give learners foundation...
Joan T. Merrill, MD - New Directions in Kinase Inhibition in Systemic Lupus Erythematosus: Emerging Evidence From Copenhagen
August 02, 2022 23:00 - 29 minutes VideoGo online to PeerView.com/XJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic lupus erythematosus (SLE) is an autoimmune disease associated with substantial morbidity and mortality, especially in women. The disease causes progressive damage to multiple organ systems and reduces quality of life. Improving your understanding of SLE heterogeneity at the clinical and mechanistic level can drive significant improvements across the ca...
Prof. Dr. med. Stephan Stilgenbauer - New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management
July 25, 2022 23:00 - 1 hour VideoGo online to PeerView.com/DPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The emergence and validation of the Bruton tyrosine kinase (BTK) inhibitor agent class in chronic lymphocytic leukemia (CLL) has informed the modern, more personalized approach to patient management—are you prepared to challenge your skills and see how the experts navigate this changed clinical landscape? Find out by viewing this Clinical Consults educational a...
Luke Maese, DO - Applying Therapeutic Innovations Against ALL: From Updated Evidence to Everyday Practice
July 22, 2022 23:00 - 25 minutes VideoGo online to PeerView.com/DGJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you up to date on recent evidence on acute lymphoblastic leukemia (ALL) emerging from major scientific congresses? In this activity, an ALL specialist explores recent evidence presented at the 2022 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings on developments in various treatment modalities for ALL. W...
Ashish M. Kamat, MD, MBBS - Transforming Bladder Cancer Treatment: Essential Guidance for Urologists on Therapeutic Selection, Safety, and Sequencing Along the Disease Continuum
July 22, 2022 23:00 - 1 hour VideoGo online to PeerView.com/RMY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, the research on actionable targets in bladder cancer has l...
Shmuel Shoham, MD - Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge
July 21, 2022 23:00 - 48 minutes VideoGo online to PeerView.com/EWZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Solid organ transplant recipients may be at increased risk for COVID-19 because they are immunosuppressed and less likely to mount effective immune responses to vaccination. In this educational symposium based on a live event, a panel of expert faculty address the identification of transplant patients who would likely derive benefit from anti-SARS-CoV-2 monoclo...
Riad Salem, MD, MBA - Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic Approaches
July 21, 2022 23:00 - 1 hour VideoGo online to PeerView.com/NUC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to keep up with changes to the treatment landscape of hepatocellular carcinoma (HCC) as the choice of regimens for patients with intermediate- to advanced-stage disease continues to expand and innovative locoregional and multimodal strategies move closer to entering mainstream clinical practice? With several available treatment modalities, HCC ...
Karl D. Lewis, MD - Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment
July 21, 2022 23:00 - 1 hour VideoGo online to PeerView.com/SDX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The arrival of immunotherapy in basal cell carcinoma (BCC) increases the potential for successful treatment outcomes—are you prepared to address several practical questions related to selection and sequencing of immunotherapy, safety management, and patient monitoring? In this activity, based on a recent PeerView Live Seminars & Tumor Board educational event he...
Nina Shah, MD - The "Myelennial" Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes
July 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/YEF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In collaboration with HealthTree Foundation, this “Seminars and Tumor Board” program makes new developments in multiple myeloma (MM) care comprehensible by focusing on how the “myelennial” tool kit can be leveraged for different patient populations and in different treatment settings. Using a series of case-based sessions, our expert panelists provide instructi...
Gail J. Roboz, MD - The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care
July 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/NVX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid validation of novel cytotoxic, targeted, and epigenetic treatment approaches in acute myeloid leukemia (AML) has quickly augmented—and in some cases, eclipsed—long-standing options centered around standard cytarabine-based regimens. These developments have afforded clinicians the opportunity to develop truly personalized treatment protocols designed t...
David P. Carbone, MD, PhD - Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease
July 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/RGK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Cancer immunotherapies in the form of anti–PD-1, anti–PD-L1, and anti–CTLA-4 immune checkpoint inhibitors (ICIs) have transformed the treatment of advanced and metastatic NSCLC without actionable genomic alterations, with a number of single-agent and combinatorial options available for clinical use. In light of demonstrably improved outcomes in the metastatic s...
Robert I. Haddad, MD - The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care
July 20, 2022 23:00 - 1 hour VideoGo online to PeerView.com/HVY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What is your sense of the “next steps” with practice-changing immunotherapy options for head and neck cancer (HNC)? Future advances will likely be driven by longer-term evidence in recurrent/metastatic disease, the use of immunotherapy in conjunction with surgery and radiotherapy, the potential of novel combinatorial regimens, and the emergence of newer PD-1–ta...
Aditya Bardia, MD, MPH - Navigating the Shifting Treatment Paradigm in ER+/HER2- Breast Cancer: Harnessing Modern Treatment Options and the Expanding Evidence Base to Better Patient Care and Outcomes in Early and Advanced Disease
July 20, 2022 23:00 - 57 minutes VideoGo online to PeerView.com/KVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. CDK4 and 6 inhibitors and endocrine therapy have significantly improved outcomes in ER+/HER2- advanced breast cancer, and recently, the first CDK4 and 6 inhibitor was approved in combination with endocrine therapy in the adjuvant setting for patients with HR+/HER2-, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score of ≥20%. However...
David Alain Wohl, MD - Increasing PrEP Uptake and Confident Use for HIV Prevention in Diverse Communities
July 19, 2022 23:00 - 34 minutes VideoGo online to PeerView.com/BED860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in infectious diseases and a collection of individuals at risk for being exposed to HIV describe the benefits of pre-exposure prophylaxis (PrEP), particularly with diverse communities and vulnerable populations such as Black women, same gender-loving Black and/or Latinx men, and transgender men and women. Upon completion of this acti...
Toni K. Choueiri, MD - Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care
July 19, 2022 23:00 - 1 hour VideoGo online to PeerView.com/TJS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The rapid expansion of the renal cell carcinoma (RCC) therapeutic landscape has opened doors for clinical practice advancements for medical and urologic oncologists. The long-term data supporting the efficacy of dual checkpoint blockade, together with further follow-up reported for established immunotherapy-TKI partners, as well as new efficacious combinations,...
Richard S. Finn, MD - Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care
July 12, 2022 23:00 - 1 hour VideoGo online to PeerView.com/NGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared for new standards of care in HCC management—and the implications for optimized, sequential treatment? Find out by viewing this educational activity, based on a recent PeerView Live event, where our experts will demonstrate how to develop a highly personalized management model in HCC that exploits potent new immunotherapy combinations, modern TK...
Lisa H. Lancaster, MD - The Power of Interprofessional Teams in SSc-ILD: From Diagnosis Through Management
July 11, 2022 23:00 - 34 minutes VideoGo online to PeerView.com/TDE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Systemic sclerosis (SSc) or scleroderma is a rare, often fatal connective tissue disease that affects multiple organ systems. Pulmonary involvement, particularly interstitial lung disease (ILD), occurs in the majority of patients with SSc and is now the number one cause of death in SSc. Early diagnosis is key and relies on evaluation of signs and symptoms, pulm...
David Weidman, MD - Therapeutic Advances in the Early Treatment of Alzheimer’s Disease: Expert Insights on Novel Biomarkers and Emerging Disease-Modifying Therapies
July 11, 2022 23:00 - 36 minutes VideoGo online to PeerView.com/YFY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in neurology discuss advances in the early treatment of Alzheimer’s disease, including novel biomarkers and emerging disease-modifying therapies. Upon completion of this activity, participants should be better able to: Integrate novel biomarkers for the early detection and treatment of AD based on the latest evidence, Apply the latest ...
Reynold A. Panettieri, Jr., MD - The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins
July 11, 2022 23:00 - 31 minutes VideoGo online to PeerView.com/NDA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with severe asthma, uncontrolled symptoms, and exacerbations are at risk of losing lung function over time. Despite the availability of numerous treatments, many patients with severe asthma remain uncontrolled. Evolving insights into the pathophysiology of severe asthma have led to the development of biologic therapies that target epithelial alarmins, ...
Zev A. Wainberg, MD - Targeting TIGIT to Extend Immunotherapy Benefits to More Cancer Patients: A Strategy to Amplify Immune Response and Enhance or Restore Antitumor Activity
July 08, 2022 23:00 - 55 minutes VideoGo online to PeerView.com/EBJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The discovery of immune checkpoints that regulate immune responses transformed cancer care, and the impact that the new class of immune checkpoint inhibitors (ICIs) has had in oncology cannot be understated. A proportion of patients achieve remarkable and durable responses and improved overall survival with use of the current ICIs. However, there are a number o...
Jeanne M. Palmer, MD - The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting
July 08, 2022 23:00 - 1 hour VideoGo online to PeerView.com/BJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The past decade has seen new insights into the cytogenetics, molecular genetics, and disease biology of myelofibrosis (MF), including the approval of first- and second-generation JAK inhibitors and newer evidence on using JAK inhibitors in conjunction with hematopoietic stem cell transplantation (HCT). How can all of these advances be employed in an effective a...
John N. Allan, MD - Reaping the Rewards of Innovative Care in CLL: From Targeted Strategies to Cellular Therapy
July 06, 2022 23:00 - 59 minutes VideoGo online to PeerView.com/GUR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gain the skills you need to adapt your current management protocols to reflect the new treatment reality in chronic lymphocytic leukemia (CLL), utilize novel combinatorial and sequential strategies, and map out the role of emerging cell-based therapies! In this activity, expert hematologist-oncologists provide expert guidance on the transformed nature of modern...
James M. Foran, MD, FRCPC - Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT
July 06, 2022 23:00 - 53 minutes VideoGo online to PeerView.com/HJG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science has dramatically altered the current clinical consensus on personalized care for HCT-eligible AML patients and supported the use of a variety of options (depending on a patient’s baseline characteristics). In this activity from the 2022 Tandem meetings, our expert panelists use a case-based format to tackle these new developments and provide instruc...
Leslie Kean, MD, PhD - Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols
July 04, 2022 23:00 - 56 minutes VideoGo online to PeerView.com/KPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Recent clinical developments have transformed the management of graft-versus-host disease (GVHD) and have the potential to increase access to transplants and improve post-HCT outcomes. These advances are centered on the emergence and continued research of several novel modalities, including the BTK inhibitor ibrutinib, JAK inhibitor ruxolitinib, and the T-cell ...
Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
July 04, 2022 23:00 - 1 hour VideoGo online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations wi...
Michael R. Bishop, MD - CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma
July 04, 2022 23:00 - 58 minutes VideoGo online to PeerView.com/DRW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Do you know the best practices for integrating chimeric antigen receptor (CAR)-T cell therapy into the management of patients with hematologic malignancies? Within the past few years, the indications for CAR-T therapy in leukemic and lymphoid malignancies have expanded significantly and now include acute lymphoblastic leukemia and multiple types of non-Hodgkin’...
Petros Grivas, MD, PhD - Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum
June 24, 2022 23:00 - 1 hour VideoGo online to PeerView.com/MWV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With the recent approval of multiple novel therapeutics for patients with bladder cancer, oncology professionals have increased opportunities to improve outcomes in a variety of settings. However, not all patients are being given these promising new treatments. Management protocols often do not include the latest strategies, and clinicians often have several qu...
Kimberly A. Brown, MD, FAASLD, FAST, AGAF - Refractory Ascites and Esophageal Variceal Hemorrhage: Practical Guidance to Improve Patient Outcomes
June 16, 2022 23:00 - 36 minutes VideoGo online to PeerView.com/XNU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert on refractory ascites and esophageal variceal hemorrhage (EVH) discusses evidence-based strategies to improve patient outcomes. Upon completion of this activity, participants should be better able to: Summarize the prevalence, pathophysiology, and consequences of decompensated cirrhosis and portal hypertension (eg, refractory ascites...
April W. Armstrong, MD, MPH / Kenneth B. Gordon, MD - Fine-Tuning the JAK/STAT Pathway in Psoriasis: Safely Targeting the Underlying Mechanisms of Disease With TYK2 Inhibition
June 14, 2022 23:00 - 1 hour VideoGo online to PeerView.com/CCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in dermatology discuss the role of the JAK/STAT pathway in psoriasis, as well as treatment with novel kinase inhibitors for the management of patients with psoriasis. Upon completion of this activity, participants should be better able to: Describe and differentiate targeting of the TYK2, JAK1, JAK2, and JAK3 kinases and the correlatio...